Dr. Kamgar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
Wauwatosa, WI 53226Phone+1 414-805-1000
Summary
- Dr. Mandana Kamgar is an oncologist in Wauwatosa, WI. She is a gastrointestinal oncologist with expertise in pancreaticobiliary cancers. She is part of the pancreatic cancer program at the Medical College of Wisconsin.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2016 - 2019
Cook County Health and Hospitals SystemResidency, Internal Medicine, 2013 - 2016
Tehran University of Medical Sciences School of MedicineClass of 2010
Certifications & Licensure
WI State Medical License 2019 - 2025
MI State Medical License 2016 - 2019
IL State Medical License 2013 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma Start of enrollment: 2022 Oct 31
Roles: Contact, Principal Investigator
- Determining Individualized Cancer Therapy in Pancreatic Cancer Start of enrollment: 2023 Dec 04
Roles: Contact, Principal Investigator
- A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy Start of enrollment: 2023 Feb 07
Roles: Principal Investigator, Sponsor-Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer.Kellie L Bodeker, Brian J Smith, Daniel J Berg, Chandrikha Chandrasekharan, Saima Sharif
Redox Biology. 2024-11-01 - Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes.Sara E Beltran Ponce, Christina J Small, Talha Ahmad, Kishan Patel, Susan Tsai
Practical Radiation Oncology. 2024-09-07 - 7 citationsTranscriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.Ben George, Olga Kudryashova, Andrey Kravets, Samih Thalji, Subramaniam Malarkannan
Gastroenterology. 2024-05-01
Journal Articles
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal AdenocarcinomaAzmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, Mohammad R, Philip PA, Clin Cancer Res, 3/15/2020
- PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine TumorsMpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS., Cancers (Basel), 11/29/2019
Press Mentions
Cancer Metabolism Drug Studied at Karmanos Moves into the Phase 1 Clinical Trial Stage, Targets Late-Stage Pancreatic CancerJanuary 9th, 2023- Experimental Study Is Underway for Pancreatic CancerJune 8th, 2022
- Pancreatic Cancer Survivor Shares His Story, Optimism About FutureNovember 28th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
